Previous 10 | Next 10 |
Clinical stage biopharmaceutical company Athenex (ATNX) has acquired immunotherapy developer Kuur Therapeutics in a deal valued at $185M, in a bid to bolster its cell therapy portfolio.The deal includes an upfront payment of $70M and potential milestone payments of up to $...
Transformative, leading allogeneic NKT cell platform technology expands Athenex’s cell therapy development capability Platform has broad applications based on transducing NKT cells with chimeric antigen receptors (CARs) and T cell receptors (TCRs) to target hematological ...
BUFFALO, N.Y., April 27, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will pro...
Shares of Athenex Inc. (NASDAQ:ATNX) traded at a new 52-week low today of $3.77. This new low was reached on approximately average trading volume as 5.7 million shares traded hands, while the average 30-day volume is approximately 5.1 million shares. Athenex Inc. share prices have moved ...
Insider buying decreased significantly last week. Notable Insider Buys: HighPeak Energy, Inc., William Penn Bancorporation, Bioventus Inc., Athenex, Inc., Sensei Biotherapeutics, Inc. Notable Insider Sells: Facebook, Inc., Ulta Beauty, Inc., Guardant Health, Inc., Applied Material...
Athenex received a CRL from the FDA for its lead asset Oraxol. The CRL will require them to conduct a new phase 3 trial in the US. This is a major setback for ATNX. For further details see: Athenex: The CRL Is Devastating
Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. Stocks powered higher after a slow start Friday as U.S. Treasury yields fell back from early highs. All major groups in the S&P 500 finis...
ATNX LOSSES ALERT: Bernstein Liebhard LLP is Investigating Athenex, Inc. For Violations of the Securities Laws PR Newswire NEW YORK , March 4, 2021 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, is investigating potentia...
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Athenex (ATNX) Investors with Losses to Contact Its Attorneys, ATNX Reports FDA Complete Response Letter PR Newswire SAN FRANCISCO , March 2, 2021 /PRNewswire/ -- Hagens Berman urges Athenex, Inc. (NASDAQ: ...
Image source: The Motley Fool. Athenex, Inc. (NASDAQ: ATNX) Q4 2020 Earnings Call Mar 1, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: Athenex, Inc. (ATNX) Q4 2020 Earnings Call Transcript
News, Short Squeeze, Breakout and More Instantly...
Athenex Inc. Company Name:
ATNX Stock Symbol:
NASDAQ Market:
To Best Facilitate, Company Voluntarily Files Chapter 11 Proceedings Company Has Sufficient Resources to Support Athenex Pharma Solutions Operations and Fulfill APD Customer Orders During Process BUFFALO, N.Y., May 14, 2023 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX) (...
Quantum Leap Healthcare Collaborative Announces Result of Oral Paclitaxel in Combination with a PD-1 and Carboplatin from I-SPY2 TRIAL at ASCO PR Newswire SAN FRANCISCO , May 1, 2023 /PRNewswire/ -- Quantum Leap Healthcare Collaborative (Quantum Leap) and At...
Exploring a range of strategic alternatives Revenues from product sales from continued operations increased +27% Y/Y in 4Q 2022 and +33% for full year 2022 Net Loss attributable to Athenex was $34.2 million, or $4.28 per diluted share in 4Q2022, compared to $104.4 million, or $1...